News - Anti-Arthritics/Rheumatics, Inflammatory diseases

Filter

Popular Filters

AstraZeneca lesinurad meets Ph III goal in gout patients

AstraZeneca lesinurad meets Ph III goal in gout patients

16-12-2013

Anglo-Swedish drug major AstraZeneca has released positive top-line results from LIGHT, a Phase III…

Anti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond

07-12-2013

Key clinical, corporate and regulatory events affecting the biosimilar industry have been identified…

Anti-Arthritics/RheumaticsBiosimilarsCellTrionEuropeGenericsHospiraInflammatory diseasesInflectraMarkets & MarketingRegulationRemsima

XOMA's partner Servier launches proof-of-concept clinical program for gevokizumab

25-06-2013

US drug developer XOMA Corp (Nasdaq: XOMA) says that its development partner, French independent drugmaker…

Anti-Arthritics/RheumaticsgevokizumabInflammatory diseasesPharmaceuticalResearchServierXOMA Corp

AbbVie to pay $50 million to expand GLPG0634 deal with Galapagos to Crohn's disease

17-05-2013

US drugmaker AbbVie (NYSE: ABBV) says it is extending its deal with Belgium-based Galapagos (Euronext:…

AbbVieAnti-Arthritics/RheumaticsGalapagosGLPG0634Inflammatory diseasesLicensingPharmaceuticalResearch

Concert Pharma in $300 million-plus deal with Celgene

07-05-2013

Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

SOBI links with Savient for co-promotion of Kineret in USA

19-02-2013

Swedish Orphan Biovitrum (STO: SOBI) says it has entered into an agreement with USA-based Savient Pharmaceuticals…

Anti-Arthritics/RheumaticsInflammatory diseasesKineretLicensingMarkets & MarketingNorth AmericaPharmaceuticalSavient PharmaceuticalsSobiSwedish Orphan Biovitrum

Positive opinions for Novartis' Jetrea and Ilaris from EMA advisory panel

21-01-2013

Among a number of positive recommendations last Friday from the European Medicines Agency's Committee…

Anti-Arthritics/RheumaticsEuropeIlarisInflammatory diseasesJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

Phenex in up to $135 million research collaboration with Janssen

17-12-2012

Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

EMA reviews hypothesis on Pandemrix hypothesis; finalizes on NSAIDs and CV events

21-10-2012

The European Medicines Agency's Committee on Human Medicinal Products (CHMP) said Friday that it has…

Anti-Arthritics/RheumaticsdiclofenacGlaxoSmithKlineibuprofenInflammatory diseasesNaproxenNeurologicalPandemrixPharmaceuticalRegulationVaccines

AstraZeneca partners with WuXi AppTec to speed novel biologic to Chinese market

11-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has formed a joint venture with China's WuXi AppTec to…

Anti-Arthritics/RheumaticsAsia-PacificAstraZenecaBiotechnologyImmunologicalsInflammatory diseasesMEDI5117MedImmuneMergers & AcquisitionsPharmaceuticalResearchWuXi Apptec

Novo Nordisk collaborates with Oxford University on RA and other inflammatory diseases research

25-04-2012

Departing from its core competence, diabetes, Danish insulin giant Novo Nordisk (NOV: N) and the Kennedy…

Anti-Arthritics/RheumaticsInflammatory diseasesNovo NordiskPharmaceuticalResearch

AstraZeneca collaborates with Amgen on five MAbs

03-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

GSK exercises option for Galapagos drug candidates

21-02-2012

Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top